Herman Silljé

Biologist

Herman Silljé (1969) obtained  his Ph.D. in biotechnology at the University of Utrecht in the Netherlands. He completed a postdoctoral fellowship at the University of Geneva in Switzerland, and worked as a group leader at the Max Planck Institute for Biochemistry  in Germany. He was  scientific director of Kiadis Pharma, a biopharmaceutical company focused on cell-based immunotherapy that is now listed on the Euronext Amsterdam/Brussels stock exchange market.

During the last 10 years Dr. Silljé has been in charge of the preclinical cardiology laboratory at the UMCG in Groningen and is principal investigator in the division of Experimental Cardiology at the UMCG Cardiology Research Institute.

Contact details

Current activities

Dr. Silljé is involved in numerous studies with a focus on inherited cardiomyopathies and heart failure research.  Key investigations  include the unraveling the PLN-R14del cardiomyopathy disease mechanisms and identification and of heart failure biomarkers.

My projects

PLN cardiomyopathy

Investigating and treating phospholamban cardiomyopathy

STOP-HF

Stem cell models to unravel the susceptibility and resilience to develop heart failure

SECRETE-HF

Secreted factors in cardiac remodeling provoke tumorigenesis and end organ damage in heart failure

MITO-FORCE

MITOchondrial therapy to increase cardiac FORCE and enhance exercise performance

My publications

Proteome analysis of the human mitotic spindle.

Sauer G, Körner R, Hanisch A, Ries A, Nigg EA, Silljé HHW. Mol Cell Proteomics. 2005

view on publisher site

The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1.

Chan EH, Nousiainen M, Chalamalasetty RB, Schäfer A, Nigg EA, Silljé HHW. Oncogene. 2005

view on publisher site

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HHW. Arterioscler Thromb Vasc Biol. 2010

view on publisher site

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.

Du W, Piek A, Schouten EM, van de Kolk CWA, Mueller C, Mebazaa A, Voors AA, de Boer RA, Silljé HHW. Theranostics. 2018

view on publisher site

Heart Failure Stimulates Tumor Growth by Circulating Factors.

Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA. Circulation. 2018

view on publisher site